ATLASTango Therapeutics (TNGX) Q3 2026 earnings results
Tango Therapeutics (TNGX) reported EPS of $0.13 against an analyst estimate of -$0.34: a beat of $0.47 (138.2%). The quarter ended Sep 30, 2026; the company reported on Tuesday, November 10, 2026, before the open.
Status: Confirmed · 06:00 ET, Nov 10 · Source: EODHD (calendar and fundamentals, cross-checked)
Get an email before and after Tango Therapeutics reports, free with your ATLAS account
Earnings alerts are a free benefit of your ATLAS account. The company goes to your watchlist and we email you when it reports. Google signup is one click.
Create free accountTNGX Q3 2026 results at a glance
| EPS reported | $0.13 |
|---|---|
| EPS estimate | -$0.34 |
| Surprise | Beat · +$0.47 (+138.2%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 10, 2026, before the open |
| Status | Confirmed · 06:00 ET, Nov 10 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Tango Therapeutics’s Q3 2026, a calendar-year company.
Tango Therapeutics EPS surprise history: last 5 quarters
Tango Therapeutics beat the EPS estimate in 3 of its last 5 reports, with an average surprise of +83.4%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 10, 2026 | -$0.34 | $0.13 | +138.2% | Beat | – |
| Aug 11, 2026 | -$0.32 | -$0.37 | -15.6% | Miss | -7.6% |
| May 13, 2026 | -$0.31 | -$0.32 | -3.2% | Miss | +5.8% |
| Mar 5, 2026 | -$0.33 | -$0.29 | +12.1% | Beat | +37.3% |
| Nov 4, 2025 | -$0.07 | $0.13 | +285.7% | Beat | -6.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
TNGX stock reaction to the report
TNGX moved +6.86% in the first session that reflects the report (close of Nov 9, 2026 $22.74 to close of Nov 10, 2026 $24.30). Since the report: +9.28% (latest close $24.85 on Nov 12, 2026, against $22.74 before the reaction).
Next TNGX earnings report
Tango Therapeutics has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the TNGX earnings calendar.
ATLAS fair value and signal for TNGX
| Last price | $24.13 (-2.9%) |
|---|---|
| Chance of a higher close in 1 month | 45% (normal range $20.22–$27.33) |
These are model outputs from the same valuation and calibrated model as the Tango Therapeutics stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Tango Therapeutics Q3 2026 earnings: frequently asked questions
Did Tango Therapeutics beat earnings estimates for Q3 2026?
Tango Therapeutics reported EPS of $0.13 against an analyst estimate of -$0.34: a beat of $0.47 (138.2%).
When did Tango Therapeutics report Q3 2026 results?
Tango Therapeutics reported on Tuesday, November 10, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does TNGX beat EPS estimates?
In its last 5 reports with a recorded result, Tango Therapeutics beat the EPS estimate 3 times; the average surprise was +83.4%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer